ResearcherAmsterdam University Medical CentersActive in the last 2 years
Marjolein F. Lansbergen
Matched on ORCID iD 0000-0002-0543-0486; OpenAlex author ID A5121332711. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2024: 1 paper · 2025: 2 papers · 2026: 2 papers
Papers 5
- Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant T… Co-author DOI 10.1002/ijc.70519↗
- Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. Co-author DOI 10.1158/0008-5472.can-24-4707↗
- KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancer. Co-author DOI 10.1016/j.medj.2025.100601↗
- Patient preferences for pancreatic cancer treatment (PERSEUS): a multicenter discrete choice experiment. Co-author DOI 10.1186/s12955-025-02440-5↗
- Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. Co-author DOI 10.1016/j.trsl.2024.08.002↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Johanna W. Wilmink · 5 shared papers, 2024–2026 · strength 1.07
- Paper Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. DOI 10.1158/0008-5472.can-24-4707↗
- Paper Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy … DOI 10.1002/ijc.70519↗
- Paper KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancre… DOI 10.1016/j.medj.2025.100601↗
- Hanneke W.M. van Laarhoven · 5 shared papers, 2024–2026 · strength 1.07
- Paper Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. DOI 10.1158/0008-5472.can-24-4707↗
- Paper Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy … DOI 10.1002/ijc.70519↗
- Paper KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancre… DOI 10.1016/j.medj.2025.100601↗
- Maarten F. Bijlsma · 5 shared papers, 2024–2026 · strength 1.07
- Paper Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. DOI 10.1158/0008-5472.can-24-4707↗
- Paper Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy … DOI 10.1002/ijc.70519↗
- Paper KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancre… DOI 10.1016/j.medj.2025.100601↗
- Paul Manoukian · 3 shared papers, 2024–2026 · strength 0.65
- Paper Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. DOI 10.1158/0008-5472.can-24-4707↗
- Paper Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy … DOI 10.1002/ijc.70519↗
- Paper Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. DOI 10.1016/j.trsl.2024.08.002↗
- Mark P.G. Dings · 3 shared papers, 2024–2026 · strength 0.64
- Paper Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. DOI 10.1158/0008-5472.can-24-4707↗
- Paper KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancre… DOI 10.1016/j.medj.2025.100601↗
- Paper Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. DOI 10.1016/j.trsl.2024.08.002↗
- Geert Kazemier M · 2 shared papers, 2026 · strength 0.46
- Ignace H. J. T. de Hingh · 2 shared papers, 2025–2026 · strength 0.43
- Marc G. Besselink · 2 shared papers, 2025–2026 · strength 0.43
- Judith de Vos‐Geelen · 2 shared papers, 2025 · strength 0.42
- Paper KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancre… DOI 10.1016/j.medj.2025.100601↗
- Paper Patient preferences for pancreatic cancer treatment (PERSEUS): a multicenter discrete choice experiment. DOI 10.1186/s12955-025-02440-5↗
- Marjolein Y.V. Homs · 2 shared papers, 2025 · strength 0.42
- Paper KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancre… DOI 10.1016/j.medj.2025.100601↗
- Paper Patient preferences for pancreatic cancer treatment (PERSEUS): a multicenter discrete choice experiment. DOI 10.1186/s12955-025-02440-5↗
- Joanne Verheij · 2 shared papers, 2024–2026 · strength 0.41
- Paper Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy … DOI 10.1002/ijc.70519↗
- Paper Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. DOI 10.1016/j.trsl.2024.08.002↗
- Frederike Dijk · 2 shared papers, 2024–2026 · strength 0.41
- Paper Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy … DOI 10.1002/ijc.70519↗
- Paper Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. DOI 10.1016/j.trsl.2024.08.002↗
- Nienke Petronella Maria Wassenaar · 1 shared paper, 2026 · strength 0.24
- Vincent Erwin de Meijer · 1 shared paper, 2026 · strength 0.23
- Martijn W.J. Stommel · 1 shared paper, 2026 · strength 0.23
- Casper H.J. van Eijck · 1 shared paper, 2026 · strength 0.23
- Simone Augustinus · 1 shared paper, 2025 · strength 0.20
- Pauline A. J. Vissers · 1 shared paper, 2025 · strength 0.20
- Izaak Quintus Molenaar · 1 shared paper, 2025 · strength 0.20
- Bert A. Bonsing · 1 shared paper, 2025 · strength 0.20
- Brigitte C.M. Haberkorn · 1 shared paper, 2025 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.